Camel-IDS
STRIKE THE CANCER, NOT THE PATIENT

Spin-off of VUB's Molecular Imaging research group and the Nuclear Medicine Dept. of UZ Brussel

Established in 2015

Milestones

- **2014:** First publications from the MIMA research group, demonstrating cancer therapy in rodents using sdAbs coupled to a therapeutic radio-isotope.
- **October 2014:** Incorporation of Camel-IDS N.V. in Brussels.
- **December 2014:** Innoviris Explore grant providing funding for a first-in-human biodistribution study of anti-Her2 sdAbs coupled to a therapeutic radio-isotope.
- **June 2015:** License agreement with VUB, establishing Camel-IDS as VUB spin-off.
- **July 2015:** Seed financing round with 3 private investors and Fondation Fournier Majoie.
- **December 2015:** Second Innoviris Explore grant providing funding for initiating preclinical development of two additional compounds targeting other cancer indications.
- **2016:** Camel-IDS-sponsored first-in-human biodistribution study at the UZ Brussel of anti-Her2 sdAbs, coupled to a therapeutic radio-isotope.

Camel-IDS

[E] info@camel-ids.com
[W] www.camel-ids.com

Fast and specific therapeutic radiation of cancer cells. Sparing healthy tissues.

Camel-IDS is a spin-off of VUB's Molecular Imaging (MIMA) research group and the UZ Brussel Nuclear Medicine Department, headed by Prof. Tony Lahoutte.

Camel-IDS leverages recombinant, small antigen-binding fragments derived from Camelidae heavy-chain-only antibodies (sdAbs), otherwise called VHHs. These Camelidae-derived probes are used to transport therapeutic radioisotopes to selected target receptors on the cancer cell surface and will selectively kill cancer cells by irradiation.

These radiolabeled sdAbs represent a new class of drugs with superior pharmacokinetic properties compared to any other antibody based drug currently on the market, setting the foundation for fast, specific and therapeutically effective delivery of cytotoxic radiation to cancer cells, while sparing healthy tissues.

Developing new therapeutic options for cancer.

Our first lead compound is a radiopharmaceutical drug for treatment of Her2 positive cancer, offering oncologists new treatment options in both breast & gastric cancer.

By developing a new class of drugs with a distinct mode of action, we aim to address the unmet medical need of patients with metastatic Her2 positive disease, developing resistance to the currently marketed drugs. In addition, our compounds are selected for

an excellent safety profile and for the possibility of co-administration with the currently marketed drugs, leaving the option open for entry at an earlier stage of the disease.

Camel-IDS develops a pipeline of these first in class products with the intention to test safety and efficacy in Phase I and II clinical trials. For Phase III clinical trials and marketing we foresee to partner with a larger global (radio)pharmaceutical company per product.

A Phase 1 trial in Her2 positive breast cancer is ongoing in 2016. In parallel, preclinical lead compound selection is ongoing for additional targets in other cancer indications.

Networks of expertise and support.

Camel-IDS has its exploitation site in the Brussels Region on the VUB medical campus. Through close collaboration with both VUB and UZ Brussel as well as VIB, the company has its roots in the fruitful cradle of the sdAbs technology.

Camel-IDS' innovative preclinical and clinical research programs have been financially supported by two grants of the Brussels Region (Innoviris Explore) and have benefited from the business support by LifeTech Brussels.



Camel-IDS develops targeted radionuclide therapeutic solutions for cancer patients, aimed at fast and specific delivery of therapeutic radiation to selected receptors on the cancer cell surface, while sparing healthy tissues.



Camel-IDS uses single-domain antibody fragments of Camelidae heavy-chain antibodies (called VHHs or sdAbs) as transport vehicles for radioisotopes.

'Camel-IDS is driven by the ambition to translate innovative concepts on radioimmuno-therapeutics, developed at VUB, into a new class of drugs for cancer patients, combining a clear therapeutic impact with minimal background toxicity.'

Tony Lahoutte, co-founder

innoviris .brussels empowering research

Universitair Ziekenhuis Brussel

Knowledge & Technology Transfer Interface

Knowledge & Technology Transfer Interface (KTI)
Vrije Universiteit Brussel • Pleinlaan 2 • B-1050 Brussel • Belgium
[E] techtransfer@vub.ac.be • [W] www.vubtechtransfer.be • [T] +32 (0)2 629 22 07

Vrije Universiteit Brussel

04-16 - Published by: VUB - TTI, Sonja Haesen, Pleinlaan 2, 1050 Brussel